JP5267969B2 - 癌ワクチン - Google Patents
癌ワクチン Download PDFInfo
- Publication number
- JP5267969B2 JP5267969B2 JP2007313856A JP2007313856A JP5267969B2 JP 5267969 B2 JP5267969 B2 JP 5267969B2 JP 2007313856 A JP2007313856 A JP 2007313856A JP 2007313856 A JP2007313856 A JP 2007313856A JP 5267969 B2 JP5267969 B2 JP 5267969B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cancer
- cell
- sox6
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940022399 cancer vaccine Drugs 0.000 title claims description 22
- 238000009566 cancer vaccine Methods 0.000 title claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 86
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 44
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 31
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 28
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 142
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 16
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 16
- 201000002528 pancreatic cancer Diseases 0.000 claims description 16
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- 208000032612 Glial tumor Diseases 0.000 claims description 15
- 206010018338 Glioma Diseases 0.000 claims description 15
- 206010029260 Neuroblastoma Diseases 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 102100036694 Transcription factor SOX-6 Human genes 0.000 claims description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 101000642517 Homo sapiens Transcription factor SOX-6 Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 16
- 239000000427 antigen Substances 0.000 abstract description 14
- 108091007433 antigens Proteins 0.000 abstract description 14
- 102000036639 antigens Human genes 0.000 abstract description 14
- 201000011510 cancer Diseases 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 5
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000012636 effector Substances 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 230000000638 stimulation Effects 0.000 description 17
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 210000005087 mononuclear cell Anatomy 0.000 description 11
- 230000006378 damage Effects 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 101150055666 sox6 gene Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710198028 Transcription factor SOX-6 Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007313856A JP5267969B2 (ja) | 2007-12-04 | 2007-12-04 | 癌ワクチン |
| PCT/JP2008/072046 WO2009072555A1 (fr) | 2007-12-04 | 2008-12-04 | Vaccin contre le cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007313856A JP5267969B2 (ja) | 2007-12-04 | 2007-12-04 | 癌ワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009137857A JP2009137857A (ja) | 2009-06-25 |
| JP5267969B2 true JP5267969B2 (ja) | 2013-08-21 |
Family
ID=40717732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007313856A Expired - Fee Related JP5267969B2 (ja) | 2007-12-04 | 2007-12-04 | 癌ワクチン |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP5267969B2 (fr) |
| WO (1) | WO2009072555A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010285870A (ja) | 2009-06-09 | 2010-12-24 | Denso Corp | 筒内圧センサの瞬断検出装置、内燃機関の制御装置 |
| JPWO2012141201A1 (ja) * | 2011-04-11 | 2014-07-28 | 公立大学法人大阪市立大学 | 癌免疫療法のためのペプチド及びその利用 |
| CA2833173C (fr) * | 2011-04-20 | 2023-09-05 | University Of Washington Through Its Center For Commercialization | Cellules deficientes en beta-2 microglobuline |
| CN109952308B (zh) * | 2016-11-29 | 2022-09-23 | 武汉华大吉诺因生物科技有限公司 | 多肽及其应用 |
| WO2018098715A1 (fr) * | 2016-11-30 | 2018-06-07 | 深圳华大基因研究院 | Polypeptide et son application |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2794370B1 (fr) * | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| WO2003018629A1 (fr) * | 2001-08-23 | 2003-03-06 | In2Gen Co., Ltd. | Antigene cage |
| WO2006077941A1 (fr) * | 2005-01-19 | 2006-07-27 | Keio University | Vaccin contre le cancer |
| JP4840858B2 (ja) * | 2006-03-16 | 2011-12-21 | 学校法人慶應義塾 | 癌ワクチン |
-
2007
- 2007-12-04 JP JP2007313856A patent/JP5267969B2/ja not_active Expired - Fee Related
-
2008
- 2008-12-04 WO PCT/JP2008/072046 patent/WO2009072555A1/fr active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009137857A (ja) | 2009-06-25 |
| WO2009072555A1 (fr) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1548032B1 (fr) | Peptides kdr et vaccins les renfermant | |
| JP2019050826A (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| TW202110875A (zh) | 病毒載體及其在授受性細胞療法之應用 | |
| JP5267969B2 (ja) | 癌ワクチン | |
| JP2021038225A (ja) | ネコ用がんワクチン | |
| JP2018511320A (ja) | 治療およびエピトープマッピング用Ｔ細胞の感作および増殖のためのｉｎ ｖｉｔｒｏ人工リンパ節法 | |
| WO2012144726A2 (fr) | Protéines antigéniques tumorales ou gènes de la kinase 1 de type polo | |
| JPWO2008016141A1 (ja) | Ｈｌａ−ａ２４分子結合性ｋｉｆ由来ペプチド | |
| JP4840858B2 (ja) | 癌ワクチン | |
| Schmitz et al. | Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11 | |
| JP4840866B2 (ja) | 癌ワクチン | |
| US11548925B2 (en) | CACNA1H-derived tumor antigen polypeptide and use thereof | |
| AU2018250926B2 (en) | Methods to produce peptides, polypeptides or cells for modulating immunity | |
| JP5709396B2 (ja) | がんワクチン | |
| JP6604975B2 (ja) | 免疫細胞療法のためのペプチドスクリーニング方法 | |
| US11612643B2 (en) | Col14A1-derived tumor antigen polypeptide and use thereof | |
| CN106117334B (zh) | 一种肿瘤抗原mage3的ctl识别表位肽及其应用 | |
| JP5984113B2 (ja) | がん免疫療法 | |
| KR101203979B1 (ko) | Ｒｎａ 전이 항원 제시 세포를 이용한 신규 종양항원의 규명 방법 | |
| JP2021013301A (ja) | メソテリン由来のｈｌａ−ａ２４拘束性エピトープペプチド | |
| WO2016159286A1 (fr) | Méthode de production d'un vaccin anticancéreux, et vaccin anticancéreux | |
| JP2009035534A (ja) | Ｈｌａ−ａ２４拘束性抗原ペプチドおよびその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120911 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130318 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130409 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130426 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5267969 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |